Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy

G. P. Canellos, V. T. DeVita, J. Whang-Peng, B. A. Chabner, P. S. Schein, R. C. Young

研究成果: 雜誌貢獻文章

56 引文 (Scopus)

摘要

Thirty two patients in the blastic phase of Philadelphia chromosome positive chronic granulocytic leukemia (CGL) were studied in a prospective randomized trial in which vincristine prednisone (19 patients) was compared with cytosine arabinoside 6 thioguanine (13 patients). Seven remissions (37%), including two complete remissions, were achieved in the vincristine prednisone group. Three of the five with predominant hypodiploid blast cell lines treated with vincristine prednisone had complete or partial remissions. Both complete remitters presented with hypodiploidy consisting of 44 chromosomes. Four patients (30%) who were treated with cytosine arabinoside 6 thioguanine responded with one complete remission. The median survival of the responders was 8 mo, as compared to 1-2 mo for the nonresponders. Crossover to the opposite regimen as secondary therapy following refractoriness or resistance resulted in only 3 partial responses out of 21 treated. All three had previously responded to vincristine prednisone. Of the 32 cases, 14 had an elective splenectomy during the chronic phase of the disease. Prior splenectomy did not influence the response to chemotherapy, as all three complete remitters occurred in the nonsplenectomized group. Similarly, survival in the blastic phase was not affected by prior splenectomy.
原文英語
頁(從 - 到)1003-1009
頁數7
期刊Blood
47
發行號6
出版狀態已發佈 - 十二月 1 1976
對外發佈Yes

指紋

Leukemia, Myeloid, Chronic Phase
Chemotherapy
Vincristine
Prednisone
Splenectomy
Thioguanine
Drug Therapy
Cytarabine
Chromosomes
Philadelphia Chromosome
Survival
Therapeutics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Chronic Disease
Cells
Cell Line

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

引用此文

Canellos, G. P., DeVita, V. T., Whang-Peng, J., Chabner, B. A., Schein, P. S., & Young, R. C. (1976). Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy. Blood, 47(6), 1003-1009.

Chemotherapy of the blastic phase of chronic granulocytic leukemia : hypodiploidy and response to therapy. / Canellos, G. P.; DeVita, V. T.; Whang-Peng, J.; Chabner, B. A.; Schein, P. S.; Young, R. C.

於: Blood, 卷 47, 編號 6, 01.12.1976, p. 1003-1009.

研究成果: 雜誌貢獻文章

Canellos, GP, DeVita, VT, Whang-Peng, J, Chabner, BA, Schein, PS & Young, RC 1976, 'Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy', Blood, 卷 47, 編號 6, 頁 1003-1009.
Canellos GP, DeVita VT, Whang-Peng J, Chabner BA, Schein PS, Young RC. Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy. Blood. 1976 12月 1;47(6):1003-1009.
Canellos, G. P. ; DeVita, V. T. ; Whang-Peng, J. ; Chabner, B. A. ; Schein, P. S. ; Young, R. C. / Chemotherapy of the blastic phase of chronic granulocytic leukemia : hypodiploidy and response to therapy. 於: Blood. 1976 ; 卷 47, 編號 6. 頁 1003-1009.
@article{b5c73a90c6b54cf89b2f40c8c080fff6,
title = "Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy",
abstract = "Thirty two patients in the blastic phase of Philadelphia chromosome positive chronic granulocytic leukemia (CGL) were studied in a prospective randomized trial in which vincristine prednisone (19 patients) was compared with cytosine arabinoside 6 thioguanine (13 patients). Seven remissions (37{\%}), including two complete remissions, were achieved in the vincristine prednisone group. Three of the five with predominant hypodiploid blast cell lines treated with vincristine prednisone had complete or partial remissions. Both complete remitters presented with hypodiploidy consisting of 44 chromosomes. Four patients (30{\%}) who were treated with cytosine arabinoside 6 thioguanine responded with one complete remission. The median survival of the responders was 8 mo, as compared to 1-2 mo for the nonresponders. Crossover to the opposite regimen as secondary therapy following refractoriness or resistance resulted in only 3 partial responses out of 21 treated. All three had previously responded to vincristine prednisone. Of the 32 cases, 14 had an elective splenectomy during the chronic phase of the disease. Prior splenectomy did not influence the response to chemotherapy, as all three complete remitters occurred in the nonsplenectomized group. Similarly, survival in the blastic phase was not affected by prior splenectomy.",
author = "Canellos, {G. P.} and DeVita, {V. T.} and J. Whang-Peng and Chabner, {B. A.} and Schein, {P. S.} and Young, {R. C.}",
year = "1976",
month = "12",
day = "1",
language = "English",
volume = "47",
pages = "1003--1009",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Chemotherapy of the blastic phase of chronic granulocytic leukemia

T2 - hypodiploidy and response to therapy

AU - Canellos, G. P.

AU - DeVita, V. T.

AU - Whang-Peng, J.

AU - Chabner, B. A.

AU - Schein, P. S.

AU - Young, R. C.

PY - 1976/12/1

Y1 - 1976/12/1

N2 - Thirty two patients in the blastic phase of Philadelphia chromosome positive chronic granulocytic leukemia (CGL) were studied in a prospective randomized trial in which vincristine prednisone (19 patients) was compared with cytosine arabinoside 6 thioguanine (13 patients). Seven remissions (37%), including two complete remissions, were achieved in the vincristine prednisone group. Three of the five with predominant hypodiploid blast cell lines treated with vincristine prednisone had complete or partial remissions. Both complete remitters presented with hypodiploidy consisting of 44 chromosomes. Four patients (30%) who were treated with cytosine arabinoside 6 thioguanine responded with one complete remission. The median survival of the responders was 8 mo, as compared to 1-2 mo for the nonresponders. Crossover to the opposite regimen as secondary therapy following refractoriness or resistance resulted in only 3 partial responses out of 21 treated. All three had previously responded to vincristine prednisone. Of the 32 cases, 14 had an elective splenectomy during the chronic phase of the disease. Prior splenectomy did not influence the response to chemotherapy, as all three complete remitters occurred in the nonsplenectomized group. Similarly, survival in the blastic phase was not affected by prior splenectomy.

AB - Thirty two patients in the blastic phase of Philadelphia chromosome positive chronic granulocytic leukemia (CGL) were studied in a prospective randomized trial in which vincristine prednisone (19 patients) was compared with cytosine arabinoside 6 thioguanine (13 patients). Seven remissions (37%), including two complete remissions, were achieved in the vincristine prednisone group. Three of the five with predominant hypodiploid blast cell lines treated with vincristine prednisone had complete or partial remissions. Both complete remitters presented with hypodiploidy consisting of 44 chromosomes. Four patients (30%) who were treated with cytosine arabinoside 6 thioguanine responded with one complete remission. The median survival of the responders was 8 mo, as compared to 1-2 mo for the nonresponders. Crossover to the opposite regimen as secondary therapy following refractoriness or resistance resulted in only 3 partial responses out of 21 treated. All three had previously responded to vincristine prednisone. Of the 32 cases, 14 had an elective splenectomy during the chronic phase of the disease. Prior splenectomy did not influence the response to chemotherapy, as all three complete remitters occurred in the nonsplenectomized group. Similarly, survival in the blastic phase was not affected by prior splenectomy.

UR - http://www.scopus.com/inward/record.url?scp=0017082495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017082495&partnerID=8YFLogxK

M3 - Article

C2 - 1064434

AN - SCOPUS:0017082495

VL - 47

SP - 1003

EP - 1009

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -